Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.29 | N/A | +5.84% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.29 | N/A | +5.84% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the quarter's performance, highlighting ongoing efforts to develop their product pipeline. They remain focused on strategic initiatives but did not provide specific guidance for the future.
We are pleased with our progress this quarter.
Our focus remains on advancing our pipeline.
Tango Therapeutics I's earnings report showed a smaller-than-expected loss per share, which contributed to a significant stock increase of 36.28%. The positive stock reaction suggests that investors are encouraged by the company's progress and management's optimistic tone, despite the lack of revenue data and forward guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ADT INC DEL
Mar 2, 2026